| Prediction type | Cancer type | No of patients | Type of data | Accuracy | Validation method | Important features | Reference |
| Susceptibility | Multiple myeloma | 80 | SNPs | 71% | Leave-one-out cross-validation | Snp739514, snp521522, snp994532 | [63] |
| Susceptibility | Breast cancer | 174 | SNPs | 69% | 20-fold cross-validation | snpCY11B2 (+) 4536 T/C snpCYP1B1 (+) 4328 C/G | [64] |
| Recurrence | Breast cancer | 679 | Clinical, pathologic, epidemiologic | 89% | Hold-out | Local invasion of tumour | [65] |
| Recurrence | Cervical cancer | 168 | Clinical, pathologic | 68% | Hold-out | Pathologic_S, pathologic_T, cell type RT target summary | [66] |
| Recurrence | Breast cancer | 547 | Clinical, Population | 95% | 10-fold cross-validation | Age at diagnosis, age at menarche | [67] |
| Survival | Oral cancer | 31 | Clinical, genomic | 75% | Cross-validation | Drink, invasion, p 63 gene | [68] |
| Survival | Breast cancer | 295 | Genomic | 97% | Leave-one-out cross-validation | 50-gene signature | [69] |
| Survival | Oral cancer | 69 | Clinical, molecular | 98% | Cross-validation | TNM_stage, number of recurrences | [70] |